Cibc World Markets Corp Sells 1,561 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Cibc World Markets Corp trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 21.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,810 shares of the biopharmaceutical company's stock after selling 1,561 shares during the period. Cibc World Markets Corp's holdings in Alnylam Pharmaceuticals were worth $1,367,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ALNY. Regeneron Pharmaceuticals Inc. acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $1,045,822,000. Raymond James Financial Inc. purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $65,295,000. Jennison Associates LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $61,160,000. Proficio Capital Partners LLC lifted its stake in shares of Alnylam Pharmaceuticals by 25,929.6% during the fourth quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company's stock worth $45,570,000 after purchasing an additional 192,916 shares in the last quarter. Finally, Strategic Financial Concepts LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $41,529,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total transaction of $362,246.40. Following the transaction, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the company's stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock worth $19,958,097 over the last ninety days. 1.50% of the stock is currently owned by company insiders.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their price target for the company from $280.00 to $328.00 in a report on Monday. Bank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Sanford C. Bernstein lowered their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. Finally, Scotiabank boosted their price target on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the stock a "sector outperform" rating in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $312.30.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY traded down $11.75 during mid-day trading on Wednesday, reaching $269.21. 1,073,887 shares of the stock were exchanged, compared to its average volume of 807,879. The business has a fifty day moving average price of $258.62 and a 200 day moving average price of $260.26. The firm has a market capitalization of $34.85 billion, a PE ratio of -124.06 and a beta of 0.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.